Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Feb 21, 2012 10:20am

302 Views

Post# 19560574

RE: Oncolytics signs deal with NCIC CTG for Reolys

WOW! another Phase 2 study. People over at the Yahoo board are excited. It'll be years before this study bears fruit.It has already shown no impact on the SP.

The only,I repeat the only, effect on the SP is POSITIVE RESULTS from existing trials.

Positive results = escalation of the SP : No results = drifting of the SP (downwards).

Bullboard Posts

Arbor Metals completes Phase 1 drilling at Jarnet lithium project